Clinical trialNo phase (not a drug trial)Not yet recruiting
Evaluating the Effectiveness of AIT in the Treatment of Pain Related to Pancreatic Cancer
A Pilot Study Aimed at Evaluating the Effectiveness of AIT in the Treatment of Pain Related to Pancreatic Cancer
- Outcome
- Ongoing
- Phase
- No phase (not a drug trial)
- Status
- Not yet recruiting
- Study type
- Interventional
- Start
- September 2026
- Expected end
- December 2027
- Enrollment
- 40 participants
- Sites
- 3
- Primary outcomes
- Change in Edmonton Symptom Assessment System (ESAS) - Pain Subscore
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 10 September 2026
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The aim of this clinical trial is to assess the effectiveness of intratracheal analgesia on pain intensity in cancer patients, from the start of treatment up to 3 months. It will also investigate the safety of this technique. The main questions it seeks to answer are as follows: What is the impact on the use of opioid analgesics, and can this be measured? What is the quality of life? What is the quality of sleep, and can this be assessed? How does the patient's weight change? Is the patient satisfied? What is the patient's overall survival? The researchers will assess the equivalent daily dose of morphine (mg/day) between enrolment and follow-up visits, as well as the number of patients requiring an escalation of analgesic treatment. Overall quality of life score measured using the ESAS questionnaire between enrolment and follow-up visits; satisfaction assessed using a numerical satisfaction scale (0-10); sleep quality assessed using the ISI questionnaire; and the tolerability and safety of the technique assessed by monitoring adverse events. Eligible participants: Following implantation of the intrathecal pump, participants will have scheduled consultations at day 30, then at 3, 6, 9 and 12 months, with questionnaires to be completed.
Papers 9
- BackgroundRandomized controlled study comparing the analgesic effects of intravenous patient-controlled analgesia and patient-con… DOI 10.1016/j.hpb.2022.01.013↗
- BackgroundIntrathecal Drug Delivery Systems for Refractory Pancreatic Cancer Pain: Observational Follow-up Study Over an 11-Year … DOI 10.1213/ane.0000000000002903↗
- BackgroundIntrathecal Therapy for Cancer-Related Pain. DOI 10.1093/pm/pnw060↗
- BackgroundHistory and present state of targeted intrathecal drug delivery. DOI 10.1007/s11916-014-0474-8↗
- BackgroundIntrathecal drug delivery. DOI 10.1007/978-3-319-99124-5_188↗
- BackgroundIntrathecal analgesia. DOI 10.1016/j.anclin.2007.07.001↗
- BackgroundCancer pain. DOI 10.1001/jama.290.18.2476↗
- BackgroundCytoplasmic STAT proteins associate prior to activation. DOI 10.1042/bj3450417↗
- BackgroundAn international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Ass… DOI 10.1016/s0304-3959(99)00073-1↗